Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruitao Lin

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Biometrics|June 6, 2018
Bayesian optimal interval design with multiple toxicity constraintsRuitao Lin
Statistics in Medicine|December 11, 2014
Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. ZoharGuosheng Yin, Ruitao Lin
Journal of Biopharmaceutical Statistics|July 2, 2019
On the relative efficiency of model-assisted designs: a conditional approachRuitao Lin, Ying Yuan
Contemporary Clinical Trials|July 28, 2015
Bayes factor and posterior probability: Complementary statistical evidence to p-valueRuitao Lin, Guosheng Yin
Statistics in Medicine|August 9, 2017
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trialsRuitao Lin, Guosheng Yin
Statistical Methods in Medical Research|July 17, 2015
Bayesian optimal interval design for dose finding in drug-combination trialsRuitao Lin, Guosheng Yin
Biostatistics (Oxford, England)|August 24, 2016
Nonparametric overdose control with late-onset toxicity in phase I clinical trialsRuitao Lin, Guosheng Yin
Biometrics|April 7, 2020
Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'HaganYeonhee Park, Ruitao Lin
Biostatistics (Oxford, England)|April 16, 2019
Time-to-event model-assisted designs for dose-finding trials with delayed toxicityRuitao Lin, Ying Yuan
Pharmaceutical Statistics|August 2, 2018
Uniformly most powerful Bayesian interval design for phase I dose-finding trialsRuitao Lin, Guosheng Yin
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Biometrics|June 6, 2018
Bayesian optimal interval design with multiple toxicity constraintsRuitao Lin
Statistics in Medicine|December 11, 2014
Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. ZoharGuosheng Yin, Ruitao Lin
Journal of Biopharmaceutical Statistics|July 2, 2019
On the relative efficiency of model-assisted designs: a conditional approachRuitao Lin, Ying Yuan
Contemporary Clinical Trials|July 28, 2015
Bayes factor and posterior probability: Complementary statistical evidence to p-valueRuitao Lin, Guosheng Yin
Statistics in Medicine|August 9, 2017
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trialsRuitao Lin, Guosheng Yin
Statistical Methods in Medical Research|July 17, 2015
Bayesian optimal interval design for dose finding in drug-combination trialsRuitao Lin, Guosheng Yin
Biostatistics (Oxford, England)|August 24, 2016
Nonparametric overdose control with late-onset toxicity in phase I clinical trialsRuitao Lin, Guosheng Yin
Biometrics|April 7, 2020
Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'HaganYeonhee Park, Ruitao Lin
Biostatistics (Oxford, England)|April 16, 2019
Time-to-event model-assisted designs for dose-finding trials with delayed toxicityRuitao Lin, Ying Yuan
Pharmaceutical Statistics|August 2, 2018
Uniformly most powerful Bayesian interval design for phase I dose-finding trialsRuitao Lin, Guosheng Yin
Pageof 10